Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
LA JOLLA, Calif., Sept. 14, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Wednesday, September 21, 2016 at 9:30 a.m. PDT (12:30 p.m. EDT). The conference will be held from September 20-22, 2016 in Las Vegas.
A live audio webcast and replay will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
